Eagle Bay Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

Eagle Bay Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5,930	Closed	-$42K	–	874
2021 Q4	$42K	Buy	+5,930	New	+$48.2K	0.03%	419

Other funds holding SPRY

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Eagle Bay Advisors's SPRY Position: Q1 2022 in Review

Eagle Bay Advisors sold out of ARS Pharmaceuticals (SPRY) in Q1 2022, closing a stake of 5,930 shares — an estimated $42K sold.

Eagle Bay Advisors first reported a position in SPRY in Q4 2021 and held it in 1 quarter. The position peaked at $42K in Q4 2021. 70 funds tracked by Wall St. Rank hold SPRY as of Q1 2022.

Eagle Bay Advisors reported no remaining ARS Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Eagle Bay Advisors sold 5,930 ARS Pharmaceuticals shares in Q1 2022, an estimated $42K.
Eagle Bay Advisors first reported a position in ARS Pharmaceuticals in Q4 2021 and held it in 1 quarter.
Eagle Bay Advisors's ARS Pharmaceuticals position peaked at $42K in Q4 2021.
70 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2022.

Based on Eagle Bay Advisors's 13F filing for Q1 2022, filed 11 May 2022.